Insider Transactions in Q1 2022 at Avantor, Inc. (AVTR)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
2,027
-1.47%
|
$68,918
$34.47 P/Share
|
|
Feb 25
2022
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,866
-0.6%
|
$275,310
$35.39 P/Share
|
|
Feb 25
2022
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-0.63%
|
$20,405
$35.39 P/Share
|
|
Feb 25
2022
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
1,137
-1.57%
|
$39,795
$35.39 P/Share
|
|
Feb 25
2022
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
931
-2.88%
|
$32,585
$35.39 P/Share
|
|
Feb 25
2022
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-2.75%
|
$18,130
$35.39 P/Share
|
|
Feb 25
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-0.4%
|
$16,345
$35.39 P/Share
|
|
Feb 25
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
2,043
-1.46%
|
$71,505
$35.39 P/Share
|
|
Feb 25
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,043
-0.8%
|
$71,505
$35.39 P/Share
|
|
Feb 25
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.13%
|
$7,560
$35.39 P/Share
|
|
Feb 23
2022
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
69,885
+5.02%
|
-
|
|
Feb 23
2022
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+6.83%
|
-
|
|
Feb 23
2022
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
9,822
+11.92%
|
-
|
|
Feb 23
2022
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,311
+20.45%
|
-
|
|
Feb 23
2022
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,138
+21.43%
|
-
|
|
Feb 23
2022
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
6,044
+4.97%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+9.72%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-2.39%
|
$100,947
$33.79 P/Share
|
|
Feb 23
2022
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,621
+6.12%
|
-
|
|
Feb 23
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+8.24%
|
-
|
|
Feb 20
2022
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-3.17%
|
$15,232
$34.0 P/Share
|
|
Feb 20
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.26%
|
$11,144
$28.69 P/Share
|
|
Feb 20
2022
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,959
-0.87%
|
$372,606
$34.0 P/Share
|
|
Feb 20
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-2.34%
|
$104,448
$34.0 P/Share
|
|
Feb 20
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-1.14%
|
$43,078
$34.0 P/Share
|
|
Feb 20
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,040
-1.67%
|
$137,360
$34.0 P/Share
|
|
Feb 20
2022
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,328
-1.52%
|
$45,152
$34.0 P/Share
|
|
Jan 13
2022
|
Mark Christopher Murray EVP, Biomaterials & AT |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-4.68%
|
$33,966
$37.5 P/Share
|
|
Jan 05
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,551
-8.09%
|
$438,938
$38.65 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
59,418
-29.37%
|
$2,376,720
$40.77 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
59,418
+22.7%
|
$1,069,524
$18.45 P/Share
|
|
Jan 02
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.66%
|
$42,714
$42.14 P/Share
|
|
Jan 02
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,101
-3.24%
|
$340,242
$42.14 P/Share
|
|
Jan 02
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
6,516
-4.36%
|
$273,672
$42.14 P/Share
|
|
Jan 02
2022
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,517
-8.36%
|
$399,714
$42.14 P/Share
|